Molina Healthcare, Inc.
Managed Care and Health InsuranceFounded 1980- Updated June 2025
Reviewed by Swet Parvadiya
Last reviewed: June 2025
CorpDigest
Molina Healthcare, Inc.
Financial Performance
Last reviewed: June 2025 · By Swet Parvadiya
Revenue
$46.8B
Market Cap
$22.0B
Net Income
$1.8B
Employees
11,000
Molina Healthcare, Inc. Generated $46.8 billion in consolidated premium and service revenues for the fiscal year 2024, operating as a dominant, highly specialized managed care organization (MCO) that exclusively targets government-sponsored healthcare programs, specifically Medicaid, Medicare Advantage, and the Affordable Care Act (ACA) Marketplace. The financial model is characterized by exceptional free cash flow generation, yielding over $2.5 billion annually, which is aggressively deployed to fund a massive share repurchase program and reduce the long-term debt incurred during its strategic expansion phases. Molina Healthcare, Inc. is a dominant managed care organization that generated $46.8 billion in FY2024 revenue, operating exclusively within government-sponsored healthcare programs, including Medicaid, Medicare Advantage, and the ACA Marketplace. The financial architecture is characterized by exceptional free cash flow generation, yielding over $2.5 billion annually, which is aggressively deployed to fund a massive share repurchase program and reduce long-term debt. The financial architecture of Molina Healthcare, Inc. is built upon a highly specialized, risk-bearing managed care model that generated $46.8 billion in consolidated premium and service revenues during the fiscal year 2024, with the Medicaid segment contributing approximately 60% of this total, Medicare Advantage contributing 25%, and the ACA Marketplace contributing 15%. This leaves a gross margin of 11% to 12% to cover administrative costs, technology investments, provider network development, and corporate overhead, ultimately resulting in a net operating margin of 3.0% to 4.0%. The primary revenue drivers within the portfolio are concentrated in the Medicaid segment, anchored by the management of low-income, high-acuity populations, including children, pregnant women, and adults with complex chronic conditions, which generated approximately $28.0 billion in FY2024. The Medicare Advantage franchise represents the next largest and most rapidly growing therapeutic cluster, driven by the massive commercial success of its Dual-Eligible Special Needs Plans (D-SNPs), which cater to individuals eligible for both Medicare and Medicaid, generating approximately $11.7 billion in FY2024. The ACA Marketplace segment, which provides subsidized coverage to individuals and families purchasing insurance through state and federal exchanges, contributed approximately $7.0 billion, heavily influenced by the enhanced premium tax credits (PTC) extended by the American Rescue Plan and the Inflation Reduction Act. The financial flow of the organization is heavily skewed toward actuarial precision and claims management; in FY2024, the organization allocated approximately $2.5 billion to free cash flow generation, representing a substantial portion of its adjusted net income, while simultaneously dedicating significant cash flow to fund its massive share repurchase program and service the long-term debt incurred during its strategic expansion phases. Molina Healthcare, Inc. Generated $46.8 billion in consolidated premium and service revenues in FY2024, operating as a dominant national managed care entity that has aggressively restructured its portfolio through strategic partnerships and internal development to secure next-generation managed care IT and specialty member service assets. The organization employs approximately 11,000 people globally, allocating roughly $500 million to research and development in FY2024, representing a substantial portion of total revenue and underscoring a relentless dedication to pipeline innovation that is among the highest in the national managed care technology industry. The ability to generate over $2.5 billion in free cash flow in FY2024 provides the strategic flexibility to pursue bolt-on acquisitions, license promising early-stage assets, and invest in the digital infrastructure required to support its member-centric care models. Molina Healthcare, Inc. Reported consolidated premium and service revenues of $46.8 billion for the fiscal year 2024, representing a slight decline of 1% at constant exchange rates compared to the $47.3 billion reported in FY2023, a contraction driven primarily by the ongoing Medicaid redetermination unwind and the post-pandemic normalization of certain ACA Marketplace franchises, partially offset by the strong growth of the Medicare Advantage D-SNP platform and the newly integrated assets from internal technology development and strategic acquisitions. Despite the top-line pressure, the organization demonstrated exceptional financial discipline, achieving a core earnings per share (EPS) growth of 12% at constant exchange rates, reflecting the high operating leverage of its newer Medicare Advantage franchises and rigorous cost-management initiatives across the commercial and R&D divisions. The Medicaid division generated the vast majority of the $46.8 billion in sales, with the US Medicaid franchise contributing approximately $28.0 billion, a demonstration of the successful commercialization of high-acuity Medicaid populations, complex chronic condition management, and the newer targeted therapies from internal development and strategic partnerships, which are effectively offsetting the decline of older, low-acuity Medicaid physical distribution assets. The Medicare Advantage franchise reported sales of approximately $11.7 billion, driven primarily by the massive commercial success of the D-SNP portfolio, which continues to perform strongly despite the impending retail consolidation, demonstrating the deep market penetration and provider loyalty associated with the brand. The ACA Marketplace segment reported sales of approximately $7.0 billion, driven primarily by the massive commercial success of the subsidized individual market plans, which continue to perform strongly despite the February 2024 cyberattack, demonstrating the deep market penetration and member loyalty associated with the platform. Free cash flow for the year was a strong $2.5 billion, providing the financial capacity to fund the $500 million R&D budget, service the debt incurred during the strategic acquisitions, execute the share repurchase program, and pay a dividend of $0.00 per share (note: Molina does not currently pay a dividend, focusing instead on share repurchases), totaling over $2.0 billion in distributions to shareholders through buybacks. The financial impact of the US dollar strength against other major currencies was a significant headwind in FY2024, reducing reported sales by approximately $0.5 billion, a currency translation effect that highlights the structural challenge of a US-headquartered company generating a significant portion of its revenue in euros, Canadian dollars, and other foreign currencies. These challenges are compounded by the sheer scale of the R&D investment required to sustain the technology pipeline; with approximately $500 million spent in FY2024 on health IT development, any significant product failure in late-stage assets like the AI-driven prior authorization tools or the advanced SDOH analytics pipeline would result in a massive write-off of capitalized development costs and a severe hit to investor sentiment, highlighting the high-stakes nature of the current strategic positioning. The BD&L strategy is characterized by a willingness to make bold, high-value bets on innovative platforms; the full acquisition of regional health plans for $1.0 billion in 2024 established the organization's leadership in managed care IT, while the internal development of AI-driven prior authorization tools represents a calculated entry into the lucrative revenue cycle management market, demonstrating the organization's agility in responding to emerging therapeutic opportunities.
Revenue Trend Analysis
YoY Change
-1.1%
2-Year CAGR
+2%
Peak Year
2023
Trend
Mostly Growing
Molina Healthcare, Inc. has reported revenue across 3 fiscal years, compounding at +2% annually over 2 years. The most recent year saw a 1.1% decline versus the prior year. Revenue peaked in 2023 at $47.3B. Out of 2 reported periods, 1 showed growth and 1 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2024 | $46.8B | $1.8B | -1.1% |
| FY2023 | $47.3B | — | +5.1% |
| FY2022 | $45.0B | — | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
Molina Healthcare's revenue trajectory from approximately $6 billion in 2013 to $47.3 billion in FY2023 represents one of the most dramatic revenue expansions in U.S. managed care history, driven by a convergence of policy tailwinds, geographic expansion, and strategic acquisitions. The Affordable Care Act's Medicaid expansion beginning in 2014 was the primary initial catalyst — millions of newly eligible individuals enrolled in state Medicaid programs, and Molina captured a significant share of this growth in its existing states. ACA Marketplace participation added further enrollment volumes. Organic growth continued as Molina successfully won new state Medicaid managed care contracts through competitive procurements, entering markets like Florida, Nevada, and Virginia. A series of targeted acquisitions of competitor Medicaid plans added immediate scale — the Magellan Complete Care acquisition and other tuck-in deals brought established membership bases without requiring years of organic development. The Medicare Advantage segment, particularly Dual-Eligible Special Needs Plans targeting members eligible for both Medicaid and Medicare, contributed higher per-member capitation rates that amplified revenue per enrolled individual. The pandemic era from 2020 through 2022 produced an unusual revenue surge driven by the federal government's continuous coverage provision, which prohibited states from disenrolling Medicaid members regardless of current eligibility. This artificial membership retention inflated enrollment significantly during 2021–2022, contributing to the peak revenue levels. FY2022 revenue reached approximately $45 billion and FY2023 reached $47.3 billion before declining slightly to $46.8 billion in FY2024 as the Medicaid redetermination process removed previously ineligible members from state rolls.
The Medicaid redetermination unwind beginning in 2023 was the most significant financial headwind Molina Healthcare faced in the post-Zubretsky era. The federal government's continuous coverage provision, enacted during the COVID-19 pandemic, had prevented states from disenrolling Medicaid members regardless of whether they still met eligibility requirements. This provision inflated nationwide Medicaid enrollment by an estimated 15 to 20 million individuals beyond normal eligibility levels. When Congress allowed the continuous coverage provision to expire in April 2023, states began the process of reviewing all enrolled members and disenrolling those who no longer qualified — a process expected to take 12 to 18 months to complete. For Molina, the redetermination process created membership losses in the millions, directly reducing premium revenue. The financial impact was partially offset by a compositional effect: many members disenrolled were the healthiest, most recently enrolled individuals who had joined during the pandemic. Their departure left Molina's remaining membership with higher average acuity, which technically meant higher per-member capitation rates in states that adjusted rates for acuity. However, higher-acuity members also generate higher claims costs, pressuring MCR. Molina managed the transition by simultaneously pursuing offsetting growth in Medicare Advantage D-SNP enrollment, ACA Marketplace membership, and new state contract wins. Revenue declined modestly from $47.3 billion in FY2023 to $46.8 billion in FY2024, demonstrating relative resilience compared to peers who experienced more severe membership deterioration. The redetermination process ultimately tested the company's ability to pivot enrollment mix without sacrificing profitability.
The apparent disparity between Molina Healthcare's $46.8 billion in annual revenue and its approximately $22 billion market capitalization reflects a fundamental characteristic of managed care economics — the industry operates on razor-thin margins that require enormous revenue scale to generate meaningful absolute profits. Molina's business model passes approximately 88 to 89 percent of premium revenue directly to healthcare providers as medical claims. The remaining 11 to 12 percent must cover administrative costs, leaving an operating margin of approximately 3 to 4 percent. On $47 billion of revenue, a 3.5 percent operating margin generates roughly $1.6 billion in operating income — a figure more proportionate to the market cap. Investors value managed care companies primarily on earnings multiples rather than revenue multiples, since the pass-through nature of premium revenue makes top-line numbers less meaningful than they appear. Molina's price-to-earnings ratio, enterprise value to EBITDA, and price-to-earnings-growth metrics are the operative valuation frameworks. The market cap of $22 billion implies the market values Molina at approximately 14 to 16 times forward earnings — a typical managed care multiple that reflects the predictable, recurring nature of government capitation revenue, the risks of medical cost volatility, and the political sensitivity of Medicaid funding. The company generates strong free cash flow — estimated above $1.5 billion annually — which it has deployed aggressively into share repurchases, reducing the share count and supporting earnings per share growth independent of revenue expansion. The revenue-to-market-cap ratio of roughly 0.5x is normal for managed care; it would be alarming in a software company but is entirely expected in a capital-light healthcare services business with constrained margins.
Molina Healthcare faces several material financial risks that investors and management monitor closely. The most immediately prominent is the cost impact of GLP-1 medications — drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) used for diabetes management and weight loss. These medications carry monthly costs of $800 to $1,000 or more per patient, and federal and state regulators have increasingly required Medicaid programs to cover them for qualifying diagnoses. Molina's membership — disproportionately low-income individuals with high rates of type 2 diabetes and obesity — is precisely the population most likely to qualify for GLP-1 therapy. Even a modest penetration rate across millions of members could add hundreds of millions of dollars to annual drug costs, directly pressuring MCR. A second major risk is state contract repricing or loss — if a state renegotiates capitation rates downward or awards a contract to a competitor, revenue and earnings can decline sharply. Third, political risk is endemic to the business model: federal and state budget pressures can trigger Medicaid funding cuts, enrollment restrictions, or benefit reductions that reduce Molina's revenue base. Fourth, the CMS Medicare Advantage rate-setting process introduces annual uncertainty for the Medicare segment — unfavorable rate adjustments directly reduce the economics of Molina's dual-eligible plans. Fifth, medical cost trend risk — if utilization of hospital services, specialty care, or behavioral health increases faster than capitation rates are adjusted, MCR rises above target and margins compress. Molina's management has consistently emphasized MCR discipline and actuarial pricing accuracy as the primary defense mechanisms against these risks.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Molina Healthcare, Inc. Revenue & Financials." CorpDigest, https://corpdigest.com/company/molina/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Molina Healthcare, Inc. reported $47B in revenue (FY2024).</strong><br>Source: <a href="https://corpdigest.com/company/molina/financials" target="_blank" rel="noopener">CorpDigest — Molina Healthcare, Inc. financials</a></div>